Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3820488 | 1.00 | AR (0.69) | ARCYP2C19 | |
| SCHEMBL19243489 | 0.90 | AR (0.69) | ARCYP2C19 | |
| SCHEMBL14878986 | 0.90 | AR (0.69) | ARCYP2C19 | |
| SCHEMBL20113379 | 0.90 | AR (0.69) | ARCYP2C19 | |
| SCHEMBL22626571 | 0.89 | AR (0.66) | ARCYP2C19 | |
| SCHEMBL22560838 | 0.89 | AR (0.68) | ARCYP2C19 | |
| SCHEMBL110581 | 0.89 | AR (0.68) | ARCYP2C19 | |
| SCHEMBL20646260 | 0.89 | AR (0.68) | ARCYP2C19 | |
| SCHEMBL5360052 | 0.89 | AR (0.68) | ARCYP2C19 | |
| SCHEMBL14517806 | 0.89 | AR (0.68) | ARCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186854-B2 | Process for making bicalutamide and intermediates thereof | SYNTHON IP INC. (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1546093-A1 | PROCESS FOR MAKING BICALUTAMIDE AND INTERMEDIATES THEREOF | Synthon B.V. (NL) | 2005-06-29 | — | — | EP | disclosed |
| US-6818766-B2 | USING P-FLUOROBENZENESULFINIC ACID | SYNTHON BV (NL) | 2004-11-16 | — | — | US | disclosed |
| WO-2004031136-A1 | PROCESS FOR MAKING BICALUTAMIDE AND INTERMEDIATES THEREOF | SYNTHON B.V. (NL) | 2004-04-15 | — | — | WO | disclosed |
| US-20040068135-A1 | Process for making bicalutamide and intermediates thereof | SYNTHON IP INC. | 2004-04-08 | — | — | US | disclosed |
| US-20030073742-A1 | Process for making bicalutamide and intermediates thereof | SYNTHON B.V. (NL) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073742-A1 | Process for making bicalutamide and intermediates thereof | BLVRB, BRDT, OTUB1 | AR 15/4885CYP2C19 750/4885 |
| US-20040068135-A1 | Process for making bicalutamide and intermediates thereof | BLVRB, BRDT, OTUB1 | AR 15/4885CYP2C19 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.